Collectively, our data clearly indicated that Claspin and Bcl-2 might be the targets of YTHDF3, and celastrol treatment downregulated Claspin and Bcl-2 in an m6A-YTHDF3-mediated manner in pancreatic cancer cells. The gene discussed is BCL2; the disease is familial pancreatic carcinoma.